Immunovia Provides Updates on the Price for the IMMray[TM] PanCan-d Test in the US and Improved Test Performance in the Familial/Hereditary Risk Group
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”), announced last week that its US subsidiary, Immunovia, Inc. in Marlborough, MA, received final regulatory approval to begin patient testing with the IMMray[TM] PanCan-d test, the first and only test on the market dedicated to the early detection of pancreatic cancer. Today, Immunovia announces two updates on the IMMRay[TM] PanCan-d test, regarding pricing and test performance. The IMMray[TM] PanCan-d test is being launched at a list price of 995 USD per test, which is higher than the 600 USD per test previously disclosed. The price has